MAGE-A3免疫治疗作为III期黑色素瘤辅助治疗的III期试验(DERMA)
DERMA是一项双盲、随机、安慰剂对照的III期试验,评估MAGE-A3免疫治疗在完全切除的IIIB或IIIC期MAGE-A3阳性皮肤黑色素瘤患者辅助治疗中的疗效。结论认为抗原特异性免疫治疗单药在该临床场景无效,相关开发已停止。
要点
- MAGE-A3免疫治疗未改善IIIB/IIIC期黑色素瘤患者的无病生存期。
核心结论
- MAGE-A3免疫治疗作为辅助治疗未能改善IIIB或IIIC期黑色素瘤患者的无病生存期。
- 抗原特异性免疫治疗单药在该临床场景无效,相关开发已停止。
研究设计与样本
- DERMA是一项III期、双盲、随机、安慰剂对照试验,在31个国家263个中心开展。
- 研究纳入18岁及以上、组织学证实完全切除的IIIB或IIIC期MAGE-A3阳性皮肤黑色素瘤患者,ECOG评分为0或1。
- 共1391例患者随机分组,1345例开始治疗(MAGE-A3组895例,安慰剂组450例)。
- 共同主要终点为总体人群和GS阳性人群的无病生存期。
关键数值与推荐
- 治疗前31天内,MAGE-A3组3级或以上不良事件发生率为14%(126/894),安慰剂组为12%(56/450)。
- 治疗相关3级或以上不良事件:MAGE-A3组4%(36例),安慰剂组1%(6例)。
- 两组严重不良事件发生率均为14%(MAGE-A3组129例,安慰剂组64例)。
临床怎么用
- 不推荐将MAGE-A3免疫治疗用于IIIB或IIIC期黑色素瘤的辅助治疗。
- 该研究提示抗原特异性免疫治疗单药在辅助治疗中可能无效,需探索其他策略。
局限性
- 最终分析时中位随访时间约28个月,可能不足以评估长期免疫治疗效应。
- 研究仅纳入MAGE-A3阳性且GS状态可评估的患者,结果不能外推至其他人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite newly approved treatments, metastatic melanoma remains a life-threatening condition. We aimed to evaluate the efficacy of the MAGE-A3 immunotherapeutic in patients with stage IIIB or IIIC melanoma in the adjuvant setting. METHODS: DERMA was a phase 3, double-blind, randomised, placebo-controlled trial done in 31 countries and 263 centres. Eligible patients were 18 years or older and had histologically proven, completely resected, stage IIIB or IIIC, MAGE-A3-positive cutaneous melanoma with macroscopic lymph node involvement and an Eastern Cooperative Oncology Group performance score of 0 or 1. Randomisation and treatment allocation at the investigator sites were done centrally via the internet. We randomly assigned patients (2:1) to receive up to 13 intramuscular injections of recombinant MAGE-A3 with AS15 immunostimulant (MAGE-A3 immunotherapeutic; 300 μg MAGE-A3 antigen plus 420 μg CpG 7909 reconstituted in AS01B to a total volume of 0·5 mL), or placebo, over a 27-month period: five doses at 3-weekly intervals, followed by eight doses at 12-weekly intervals. The co-primary outcomes were disease-free survival in the overall population and in patients with a potentially predictive gene signature (GS-positive) identified previously and validated here via an adaptive signature design. The final analyses included all patients who had received at least one dose of study treatment; analyses for efficacy were in the as-randomised population and for safety were in the as-treated population. This trial is registered with ClinicalTrials.gov, number NCT00796445. FINDINGS: Between Dec 1, 2008, and Sept 19, 2011, 3914 patients were screened, 1391 randomly assigned, and 1345 started treatment (n=895 for MAGE-A3 and n=450 for placebo). At final analysis (data cutoff May 23, 2013), median follow-up was 28·0 months [IQR 23·3-35·5] in the MAGE-A3 group and 28·1 months [23·7-36·9] in the placebo group. Median disease-free survival was 11·0 months (95% CI 10·0-11·9) in the MAGE-A3 group and 11·2 months (8·6-14·1) in the placebo group (hazard ratio [HR] 1·01, 0·88-1·17, p=0·86). In the GS-positive population, median disease-free survival was 9·9 months (95% CI 5·7-17·6) in the MAGE-A3 group and 11·6 months (5·6-22·3) in the placebo group (HR 1·11, 0·83-1·49, p=0·48). Within the first 31 days of treatment, adverse events of grade 3 or worse were reported by 126 (14%) of 894 patients in the MAGE-A3 group and 56 (12%) of 450 patients in the placebo group, treatment-related adverse events of grade 3 or worse by 36 (4%) patients given MAGE-A3 vs six (1%) patients given placebo, and at least one serious adverse event by 14% of patients in both groups (129 patients given MAGE-A3 and 64 patients given placebo). The most common adverse events of grade 3 or worse were neoplasms (33 [4%] patients in the MAGE-A3 group vs 17 [4%] patients in the placebo group), general disorders and administration site conditions (25 [3%] for MAGE-A3 vs four [<1%] for placebo) and infections and infestations (17 [2%] for MAGE-A3 vs seven [2%] for placebo). No deaths were related to treatment. INTERPRETATION: An antigen-specific immunotherapeutic alone was not efficacious in this clinical setting. Based on these findings, development of the MAGE-A3 immunotherapeutic for use in melanoma has been stopped. FUNDING: GlaxoSmithKline Biologicals SA.
引用
- Dreno B, Thompson JF, Smithers BM, et al. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018. PMID: 29908991. doi:10.1016/S1470-2045(18)30254-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。